The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for mavacamten, a drug intended for use in patients with hypertrophic cardiomyopathy (HCM). HCM is a genetic disorder associated with an increased risk for sudden cardiac death. The drug was developed by […]
ICER’s RWE Study of Hereditary Angioedema Treatments Provides New Insight
The Institute for Clinical and Economic Review (ICER) recently published results from a real world evidence study (RWE) assessing the efficacy and cost-effectiveness of three drugs used in cases of hereditary angioedema (HAE). The study provided a unique perspective and ICER noted an updated pricing […]
Aduhelm Approval Prompts Discussions on Reforming the FDA’s Accelerated Approval Pathway
The Food and Drug Administration (FDA)’s contentious approval of Biogen’s Aduhelm has prompted discussions on how the accelerated approval process could be reformed. The FDA’s Rick Pazdur expressed concern while a recent article co-authored by the Institute for Clinical and Economic Review (ICER)’s […]
ICER to Evaluate Value and Efficacy of Five COVID-19 Treatments
The Institute for Clinical and Economic Review (ICER) announced it will carry out assessments for five drugs used to treat COVID-19. Treatments include Regeneron’s casirivimab/imdevimab, Pfizer’s PF-07321332/ritonavir, and Merck’s molnupiravir. “Consistent with ICER’s process for announcing new […]
Aetion Researchers Discuss ICER’s Reassessment of Drugs Receiving Accelerated FDA Approval Using RWE
The Institute for Clinical and Economic Review (ICER) recently published findings from a pilot study that used real world evidence (RWE) to assess the cost-effectiveness of three drugs receiving accelerated approval from the Food and Drug Administration (FDA). The drugs are used in treating […]
ICER Revises 2018 Hereditary Angioedema Report Using RWE, Recommends Up to 75% Price Reduction
Researchers at the Institute for Clinical and Economic Review (ICER), Aetion, and the University of Washington collaborated to determine how observational real world evidence (RWE) impacted ICER’s 2018 report on hereditary angioedema therapies. ICER recommends substantial price discounts ranging for […]
Register Now for ICER’s Tuesday Webinar on Myasthenia Gravis Therapies
The Institute for Clinical and Economic Review (ICER) will hold a webinar on Tuesday, August 24th at 2:00 PM ET. President Steve Pearson will discuss preliminary findings for two drugs intended to treat myasthenia gravis, efgartigimod and eculizumab. The webinar is part of a series illustrating the […]
Novartis and University of California-Berkeley Researchers Estimate $93 Billion Wasted Yearly Across Healthcare Stakeholders, Propose Value-Based Pricing System
Researchers at the University of California-Berkeley and Novartis note that $93 billion is wasted yearly in addressing healthcare utilization management, impacting pharma, providers, patients, and payers. The authors propose a value-based system where an independent health technology assessment, […]
ICER’s Final Evidence Report on Biogen’s Aduhelm Released, Notes Insufficient Clinical Evidence for Overly Expensive Alzheimer’s Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report on aducanumab, Biogen’s infamous Alzheimer’s drug. The report highlights the lack of concrete clinical evidence regarding the drug’s clinical benefits and its high price tag. ICER recommends a yearly cost […]
ICER Announces Positive Early Results in Draft Evidence Report for Two Myasthenia Graves Therapies
The Institute for Clinical and Economic Review (ICER) has published its Draft Evidence Report on two drugs, eculizumaband efgartigimod, used in treating autoimmune disease Myasthenia Gravis (MG). Early conclusions are positive regarding the two drugs’ efficacy profiles. The deadline for public […]
